Article Data

  • Views 221
  • Dowloads 128

Original Research

Open Access

TfR associated with cervical cancer with or without neoadjuvant chemotherapy

  • Mingrong Xi1,2,†
  • Qi Cao1,2,3,†
  • Jinghan Yang4
  • Siyuan Jing4
  • Qingjie Xia5
  • Tian Tang1,2,3,*,

1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, 610041 Chengdu, Sichuan, China

2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Sichuan University, 610041 Chengdu, Sichuan, China

3Department of Reproductive Medical Center, West China Second University Hospital, 610041 Chengdu, Sichuan, China

4West China Medical School, Sichuan University, 610041 Chengdu, Sichuan, China

5West China Laboratory of Molecular Genetics, Sichuan University, 610041 Chengdu, Sichuan, China

DOI: 10.22514/ejgo.2023.010 Vol.44,Issue 1,February 2023 pp.87-92

Submitted: 18 July 2022 Accepted: 19 October 2022

Published: 15 February 2023

*Corresponding Author(s): Tian Tang E-mail:

† These authors contributed equally.


The objectives of this study was to examine the role of transferrin receptor (TfR) in the treatment of cervical cancer. Demographic and cancer-specific data were collected prospectively. Cancerous and adjacent mucosa tissues with neoadjuvant chemotherapy (NACT) or surgery alone were collected. TfR mRNA and protein expression was measured by Quantitative reverse transcription PCR (RT-qPCR) and immunoblots. We measured the cell viability by the MTT (3- [4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay with or without TfR-siRNA transfection. All 42 patients aged 49.31 ± 6.30 years with locally advanced cervical cancer were included: NACT (n = 22), surgery alone (n = 20). Quantitative results showed that the levels of TfR mRNA & protein in cancerous tissues were higher than those in adjacent mucosal tissues. We also demonstrated that the levels of TfR mRNA and protein were lower in tumor tissues collected from patients with NACT than in those collected from patients without NACT. We also observed that silencing of the TfR gene suppressed the survival of HeLa cells (48 h, p < 0.05). Our findings suggest a potential value for TfR as a diagnosis or evaluation marker for cervical cancer. The present study suggests that si-TfR may have an antitumou effect against cervical cancer cells, probably by limiting cell proliferation and reducing the TfR mRNA and protein levels.


Neoadjuvant chemotherapy; Transferrin receptor; Cervical cancer; Clinical characteristics

Cite and Share

Mingrong Xi,Qi Cao,Jinghan Yang,Siyuan Jing,Qingjie Xia,Tian Tang. TfR associated with cervical cancer with or without neoadjuvant chemotherapy. European Journal of Gynaecological Oncology. 2023. 44(1);87-92.


[1] Zou W, Han Y, Zhang Y, Hu C, Feng Y, Zhang H, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. Plos One. 2019; 14: e0225264.

[2] Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treatment Reviews. 2020; 83: 101945.

[3] de la Torre M. Neoadjuvant chemotherapy in woman with early or locally advanced cervical cancer. Reports of Practical Oncology & Radiotherapy. 2018; 23: 528–532.

[4] Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, et al. DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: an exploratory analysis. PLoS One. 2016; 11: e0149872.

[5] Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer. Oncology Research and Treatment. 2016; 39: 522–524.

[6] Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, et al. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget. 2017; 8: 107052–107075.

[7] Tang T, Xia Q, Xi M. Dihydroartemisinin and its anticancer activity against endometrial carcinoma and cervical cancer: involvement of apoptosis, autophagy and transferrin receptor. Singapore Medical Journal. 2021; 62: 96–103.

[8] Testi C, Boffi A, Montemiglio LC. Structural analysis of the transferrin receptor multifaceted ligand(s) interface. Biophysical Chemistry. 2019; 254: 106242.

[9] Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. The Journal of Membrane Biology. 2014; 247: 291–307.

[10] Dufes C, Al Robaian M, Somani S. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Therapeutic Delivery. 2013; 4: 629–640.

[11] Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. American Journal of Cancer Research. 2018; 8: 916–931.

[12] Rohner F, Namaste SM, Larson LM, Addo OY, Mei Z, Suchdev PS, et al. Adjusting soluble transferrin receptor concentrations for inflammation: biomarkers reflecting inflammation and nutritional determinants of anemia (BRINDA) project. The American Journal of Clinical Nutrition. 2017; 106: 372S–382S.

[13] Klyuchko KO, Gargin VV. Influence of neoadjuvant chemoradiotherapy for locally advanced cervical cancer. Polish Medical Journal. 2020; 48: 406–409.

[14] Xu X, Liu T, Wu J, Wang Y, Hong Y, Zhou H. Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer. Cancer Gene Therapy. 2019; 26: 356–365.

[15] Adachi M, Kai K, Yamaji K, Ide T, Noshiro H, Kawaguchi A, et al. Transferrin receptor 1 overexpression is associated with tumour de‐differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma. Histopathology. 2019; 75: 63–73.

[16] Gammella E, Buratti P, Cairo G, Recalcati S. The transferrin receptor: the cellular iron gate. Metallomics. 2017; 9: 1367–1375.

[17] Kawabata H. Transferrin and transferrin receptors update. Free Radical Biology & Medicine. 2019; 133: 46–54.

[18] Jabara HH, Boyden SE, Chou J, Ramesh N, Massaad MJ, Benson H, et al. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nature Genetics. 2016; 48: 74–78.

[19] Fu M, He Q, Guo Z, Zhou X, Li H, Zhao L, et al. Therapeutic bispecific T- cell engager antibody targeting the transferrin receptor. Frontiers in Immunology. 2019; 10: 1396.

[20] Wortham AM, Goldman DC, Chen J, Fleming WH, Zhang A, Enns CA. Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload. Journal of Biological Chemistry. 2020; 295: 3906–3917.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time